Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25811770 | 0.92 | KMT2A (0.66) | RAD52KMT2AMEN1MAPTTLR9 | |
| SCHEMBL25812546 | 0.90 | RAD52 (0.69) | RAD52KMT2AHDAC2HDAC8HDAC6 | |
| SCHEMBL25811723 | 0.85 | RAD52 (0.61) | RAD52KMT2AHDAC2HDAC8HDAC6 | |
| SCHEMBL25811765 | 0.80 | KMT2A (0.71) | RAD52KMT2AMEN1MAPTPOLB | |
| SCHEMBL25813769 | 0.80 | TLR9 (0.48) | KMT2AMEN1MAPTTLR9TLR7 | |
| SCHEMBL25811305 | 0.80 | RAD52 (0.87) | RAD52KMT2AHDAC2HDAC8HDAC6 | |
| SCHEMBL25813246 | 0.79 | LMNA (0.50) | KMT2AMEN1POLBNAMPT | |
| SCHEMBL25811242 | 0.79 | TLR9 (0.60) | RAD52KMT2AHDAC2HDAC8HDAC6 | |
| SCHEMBL25812228 | 0.77 | KMT2A (0.64) | RAD52KMT2AMEN1MAPTPOLB | |
| SCHEMBL25811739 | 0.77 | KMT2A (0.67) | RAD52KMT2AMEN1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | GALYAN BIO INC (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | HTT, HYPK, PARK7 | RAD52 1790/4885KMT2A 981/4885HDAC2 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.